At a glance
ClinicalIndex Comparison RecordN/ACompleted· 51 enrolled
Drug / intervention
Lortlatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Retrospective, Multicenter, Observational Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
In Brief
An observational study evaluating Lortlatinib for ALK-positive Non-small-cell Lung Cancer. Completed, enrolled 51 participants across 16 sites.
Detailed Summary
To evaluate the clinical real world outcomes of lorlatinib in second/later line setting anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) to TKI sequence sequence treatment after failure of alectinib as a first-line treatment in Japanese ALK positive non-small cell lung cancer (NSCLC).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsALK-positive Non-small-cell Lung Cancer
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedJul 2021
Enrollment StartAug 2021
Primary CompletionDec 2021
TodayJul 2026
First PostedJul 28, 2021
Enrollment StartAug 2, 2021
Primary CompletionDec 9, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.9 years ago
Interventions
Lortlatinibdrug
as provided in real world practice